On September 5, 2019, British Columbia announced a new policy to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases (IBD). Subsequently, Dr. Anat Fisher and colleagues in the TI’s Pharmacoepidemiology Working...
The results of many clinical trials are not publicly reported, or reported only after a long delay. Why? Dr. Richard Morrow explored the views of trial participants, scientists, and administrators in a study performed for...
This live webinar has already taken place. Scroll down to view the video recording. -- When challenged by complex cases involving people taking too many medications, we may ask: Can I stop any of these? Which should...